Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amicus Therapeutics (NQ: FOLD ) 11.42 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Amicus Therapeutics < Previous 1 2 3 Next > Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug October 17, 2024 Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA... Via Benzinga Topics Intellectual Property Lawsuit Exposures Financial Intellectual Property Legal Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday October 17, 2024 Via Benzinga Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts October 11, 2024 Via Benzinga FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 08, 2024 FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts May 14, 2024 Via Benzinga The Analyst Landscape: 4 Takes On Amicus Therapeutics December 19, 2023 Via Benzinga Amicus Therapeutics: Q1 Earnings Insights May 10, 2023 Via Benzinga The Latest Analyst Ratings for Amicus Therapeutics March 28, 2023 Via Benzinga This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today. May 14, 2024 Via Benzinga FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 09, 2024 FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Amicus Therapeutics Stock Sees RS Rating Improve To 74 March 05, 2024 In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. Via Investor's Business Daily Amicus Therapeutics Stock Sees Improved Relative Strength Rating February 09, 2024 In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. Via Investor's Business Daily 7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps November 15, 2023 These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on. Via InvestorPlace Topics Bankruptcy Exposures Financial Legal Earnings Scheduled For March 1, 2023 March 01, 2023 Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. Via Benzinga Earnings Preview: Amicus Therapeutics February 28, 2023 Via Benzinga FDA Defers Action On Amicus Therapeutics' Much Awaited Pompe Disease Therapy October 31, 2022 Via Benzinga Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session September 29, 2023 U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session. Via Benzinga Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease September 28, 2023 The FDA has approved Amicus Therapeutics' (NASDAQ: FOLD) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease. Via Benzinga Exposures Product Safety Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark September 28, 2023 Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level. Via Investor's Business Daily Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade July 20, 2023 On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81. Via Investor's Business Daily Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating July 17, 2023 On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier. Via Investor's Business Daily Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark May 19, 2023 One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday. Via Investor's Business Daily Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics May 10, 2023 The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult Via Benzinga 'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month January 25, 2023 On CNBC’s "Mad Money Lightning Round," Jim Cramer said Amicus Therapeutics Inc (NASDAQ: FOLD) is an "ideal spec. Via Benzinga Recap: Amicus Therapeutics Q3 Earnings November 07, 2022 Amicus Therapeutics (NASDAQ:FOLD) reported its Q3 earnings results on Monday, November 7, 2022 at 06:12 AM. Here's what investors need to know about the announcement. Via Benzinga Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know November 01, 2022 October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... Via Benzinga AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know October 02, 2022 Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 September 09, 2022 Upgrades Via Benzinga Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know August 31, 2022 After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. Via Benzinga iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday August 08, 2022 U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session. Via Benzinga < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
